In this webinar, Drs. Farid and Thompson discuss the latest findings on dry eye disease (DED) and treatments in the pipeline. They also share their expertise in how DED impacts patients' vision and quality of life, especially as it relates to ocular surgery outcomes.
This activity is supported by an unrestricted educational grant from Oyster Point Pharma.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Evolve Medical Education designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Vance Thompson, MD, FACS
Program Chair
Founder, Vance Thompson Vision
Professor of Ophthalmology
University of South Dakota
Sanford School of Medicine
Sioux Falls, SD
Marjan Farid, MD
Director of Cornea, Cataract, and Refractive Surgery
Vice Chair of Ophthalmic Faculty
Clinical Professor of Ophthalmology
Gavin Herbert Eye Institute
University of California, Irvine
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Vance Thompson, MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Acufocus, Alcon Vision, Allergan, Allotex, Avellino, Avisi Technologies, Bausch + Lomb, BRIM Biotechology, Carl Zeiss Meditec, Centricity, Conjtac, CSO, D&D Biopharmaceuticals, Equinox, Euclid Systems, Expert Opinion, eyeBrain Medical, Eyedetec, EyeGate Pharma, Eyesafe, FemtoVision, Foresight Robotics, Glaukos, Imprimis, iVeena, Johnson & Johnson Vision, Leica, Melt Pharmaceuticals, Ocular Innovations, OneFocus, ORA, Oyster Point Pharma, Percept, ReFocus, RxSight, Sight Sciences, Stuart Therapeutics, Tarsus Rx, TearClear, TearOptix, TherOptix, Treehouse Health, Veracity, Visant, Visus, and Vivior. Grant/Research Support: Acufocus, Alcon Vision, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Centricity, Equinox, EyeGate Pharma, Glaukos, Johnson & Johnson Vision, Sight Sciences. Speakers Bureau: Acufocus, Alcon Vision, Glaukos, Johnson & Johnson Vision. Shareholder: Acufocus, Al Optics, Allotex, Avellino, Avisi Technologies, Centricity, Conjtac, D&D Biopharmaceuticals, Equinox, Euclid Systems, Expert Opinion, eyeBrain Medical, Eyedetec, EyeGate Pharma, Eyesafe, FemtoVision, Foresight Robotics, iVeena, Melt Pharmaceuticals, Ocular Innovations, OneFocus, Oyster Point Pharma, Percept, RxSight, Sight Sciences, Stuart Therapeutics, Tarsus Rx, TearClear, TearOptix, TherOptix, Treehouse Health, Veracity, Visant, and Vivior
Marjan Farid, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, BioTissue, Carl Zeiss Meditec, CorneaGen, Dompé, Eyepoint Pharmaceuticals, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, and Novartis.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or or Oyster Point Pharma.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Justis P. Ehlers, MD, FASRS
Roger A. Goldberg, MD, MBA
Jennifer, I. Lim, MD, FASRS, FARVO
Ehsan Rahimy, MD
